Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
191 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline landscape. Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS). In RRMS, there are clear episodes of inflammatory activity (relapses). During a period of acute inflammation, old symptoms may worsen and new symptoms may appear. A relapse is when active inflammation, and the resulting symptoms, last more than 24 hours. Symptoms include tingling or numbness, double vision, fatigue, urinary urgency and weakness. Treatment includes corticosteroids and immunoglobulin therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 18, 1, 6 and 1 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively for Relapsing Remitting Multiple Sclerosis (RRMS). Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Relapsing Remitting Multiple Sclerosis (RRMS) Overview 6 Therapeutics Development 7 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies 9 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes 11 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance 12 Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies 15 Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes 17 Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development 18 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment 45 Drug Profiles 59 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects 168 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products 170 Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones 171 Appendix 185
List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2016 12 Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Number of Products under Development by Companies, H2 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 17 Comparative Analysis by Clinical Stage Development, H2 2016 18 Comparative Analysis by Early Stage Development, H2 2016 19 Products under Development by Companies, H2 2016 20 Products under Development by Companies, H2 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2016 22 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AB Science SA, H2 2016 23 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc, H2 2016 24 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H2 2016 25 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Alkermes Plc, H2 2016 26 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H2 2016 27 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H2 2016 28 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biocon Limited, H2 2016 29 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen Inc, H2 2016 30 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H2 2016 31 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Coherus BioSciences, Inc., H2 2016 32 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H2 2016 33 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GeNeuro SA, H2 2016 34 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline Plc, H2 2016 35 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H2 2016 36 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by LFB S.A., H2 2016 37 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H2 2016 38 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H2 2016 39 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H2 2016 40 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 41 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H2 2016 42 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H2 2016 43 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H2 2016 44 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H2 2016 45 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H2 2016 46 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 47 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016 48 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 49 Assessment by Monotherapy Products, H2 2016 50 Assessment by Combination Products, H2 2016 51 Number of Products by Stage and Target, H2 2016 53 Number of Products by Stage and Mechanism of Action, H2 2016 57 Number of Products by Stage and Route of Administration, H2 2016 61 Number of Products by Stage and Molecule Type, H2 2016 63 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H2 2016 173 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H2 2016 174 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H2 2016 175
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.